Key learning points:
- How hematological patient-derived xenograft (PDX) models are established
- How more super immune deficient mouse models have advanced development of hematological PDX models
- Why hematological PDX models are more translational than cell line-derived models
- How hematological PDX models can be employed in drug discovery and development
If the Patient-derived Xenografts of Hematological Malignancies: Model Systems for Drug Development and Tumor Biology Research is important to your business, act now and make the appropriate connections. See the contact information below.
|Conference/Event Dates:||04/14/2016 - 04/14/2016|
|Other Industries:||Clinical Pharmacology, Oncology-Hematology, Pharmaceutical, Professional Healthcare|
|Audience:||Directors & researchers from pharma and biotech companies, as well as CROs. This webinar may also benefit Procurement Officers and Veterinarians interested in Drug Development and Tumor Biology Research.|
|Booth Size||Booth Cost||Available Amenities|
|Marketing Vehicles Allowed:||n/a|
|Other Booth Sizes Available: n/a|
How do I show up here?
Add a note here, it is only visible by you.